Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Chirurg ; 87(2): 144-50, 2016 Feb.
Artículo en Alemán | MEDLINE | ID: mdl-26127020

RESUMEN

BACKGROUND: Peristomal skin lesions are frequent complications of ostomy; however, there is no generally accepted nomenclature and classification system. OBJECTIVE: An interdisciplinary German expert panel (GESS) composed of ten members, developed an innovative semiquantitative classification system for peristomal skin lesions for further stratification of ostomy therapy. This score is based on criteria which can be assessed by stomal therapists and treating physicians. RESULTS: The new peristomal skin lesion score grades three categories: lesion (L), status of ostomy (S) and disease (D). The L category describes the integrity of the skin as normal (L0), lesion with sustained integrity of skin (L1), integrity destroyed (L2) and local infection (L3). The S category rates the complexity of ostomy therapy as normal (S0), increased (S1) and high but not sufficiently effective (S2). The additional letters for categorization O. R. P. H. E. US describe anatomical pathologies of the stoma itself: ostomy stenosis (O), retraction (R), prolapse (P), hernia (H), edema (E) and unfavorable site (US). A systemic disorder is either absent (D0), irrelevant (D1) or relevant (D2). The LSD score is the basis for a management algorithm. CONCLUSION: The LSD score is comprehensive, standardized and holistic. Its straightforward use by health professionals can improve the consistency of the description of skin lesions and enhance the quality of ostomy therapy.


Asunto(s)
Dermatitis/clasificación , Dermatitis/diagnóstico , Complicaciones Posoperatorias/clasificación , Complicaciones Posoperatorias/diagnóstico , Enfermedades Cutáneas Infecciosas/clasificación , Enfermedades Cutáneas Infecciosas/diagnóstico , Estomas Quirúrgicos/efectos adversos , Dermatitis/terapia , Humanos , Comunicación Interdisciplinaria , Colaboración Intersectorial , Complicaciones Posoperatorias/terapia , Cuidados de la Piel/métodos , Enfermedades Cutáneas Infecciosas/terapia , Terminología como Asunto
2.
Hautarzt ; 54(10): 966-9, 2003 Oct.
Artículo en Alemán | MEDLINE | ID: mdl-14513244

RESUMEN

Common ivy (Hedera helix L.) is a ubiquitous plant in Europe whose major allergen falcarinol has moderate allergic potential. It is not related to poison ivy (Toxicodendron spp.). There are no cross reactions between the allergens of common ivy (falcarinol) and poison ivy (urushiol). Contact with common ivy or falcarinol may lead to sensitization and then a delayed hypersensitivity reaction. There are only few cases described in the literature. We report on a male hobby gardener with appropriate clinical history and positive patch test. The pathogenic mechanism is a type IV reaction following a sensitization exposure. Gardeners and landscape architects with frequent exposure to common ivy and thus a high risk of sensitization should wear appropriate protective clothing.


Asunto(s)
Dermatitis Alérgica por Contacto/etiología , Hedera/inmunología , Adulto , Alquinos , Antiinflamatorios/uso terapéutico , Valerato de Betametasona/uso terapéutico , Catecoles/inmunología , Reacciones Cruzadas , Dermatitis Alérgica por Contacto/diagnóstico , Dermatitis Alérgica por Contacto/tratamiento farmacológico , Dermatitis Alérgica por Contacto/inmunología , Diinos , Alcoholes Grasos/inmunología , Glucocorticoides/uso terapéutico , Pasatiempos , Humanos , Masculino , Pruebas del Parche
3.
Recent Results Cancer Res ; 139: 403-8, 1995.
Artículo en Inglés | MEDLINE | ID: mdl-7597307

RESUMEN

Primary malignant T cell lymphomas of the skin form a heterogenous group. Relevant classifications were recently made to separate different entities by various criteria. This is of great importance, because one should only rely on those therapeutical trials in which patients were included according such classifications. In this paper, we will mainly focus on therapeutic modalities for mycosis fungoides, which is the most frequent cutaneous T cell lymphoma and which may serve as a model disease. In principle, local (e.g., psoralens and ultraviolet A, PUVA) and systemic therapies (e.g., interferon-alpha 2a) can be applied. Very recently, we were able to demonstrate that even in initial stages of mycosis fungoides, the T cell clone is not restricted to the skin, but rather is present in low amounts in the peripheral blood. Therefore, systemic therapeutic modalities alone or in combination with local strategies (interferon-alpha 2a and acitretin/PUVA and interferon-alpha 2a) should be more effective, which will be proven by currently running clinical trials.


Asunto(s)
Linfoma Cutáneo de Células T/terapia , Neoplasias Cutáneas/terapia , Antineoplásicos/uso terapéutico , Humanos , Factores Inmunológicos/uso terapéutico , Interferón alfa-2 , Interferón-alfa/uso terapéutico , Linfoma Cutáneo de Células T/tratamiento farmacológico , Micosis Fungoide/tratamiento farmacológico , Micosis Fungoide/terapia , Terapia PUVA , Fotoféresis , Proteínas Recombinantes , Retinoides/uso terapéutico , Neoplasias Cutáneas/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA